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The application of nanotechnology to regenerative medicine has increased over recent decades. The
development of materials that can influence biology at the nanoscale has gained interest as our under-
standing of the interactions between cells and biomaterials at the nanoscale has grown. Materials that are
either nanostructured or influence the nanostructure of the cellular microenvironment have been devel-
oped and shown to have advantages over their microscale counterparts. There are several reviews which
have been published that discuss how nanomaterials have been used in regenerative medicine, particu-
larly in bone regeneration. Most of these studies have explored this concept in specific areas, such as the
application of glass-based nanocomposites, nanotechnology for targeted drug delivery to stimulate bone
repair, and the progress in nanotechnology for the treatment of osteoporosis. In this review paper, the
impact of nanotechnology in biomaterials development for bone regeneration will be discussed highlight-
ing specifically, nanostructured materials that influence mechanical properties, biocompatibility, and
osteoinductivity.
Introduction
Nanotechnology as an applicable tool for regenerative medi-
cine has gained interest as our understanding of the inter-
actions between cells and biomaterials at the nanoscale has
grown. Materials that are either nanostructured or influence
the nanostructure of the cellular microenvironment have been
studied and demonstrated to have advantages over their micro-
scale counterparts.1 We focus here on the application of nano-
technology for bone tissue regeneration as this is an extensive
field of study with an ongoing need for efficacious, novel treat-
ments as bone regeneration therapies. This review will con-
sider the many related research papers published in recent
years with the common aim of realising the potential that
nanotechnology provides to develop new strategies in bone
regeneration.
Loss of bone as a result of non-healing fractures following
trauma, disease such as osteoporosis, and as a result of
tumours affect millions of people globally, and that is one of
the leading causes of disability worldwide.2 Current materials
used in the clinic include metals, ceramics, polymers and
their composites and despite their long history and wide-
spread use, they have drawbacks including low biocompatibil-
ity, poor bone formation, and a mismatch of mechanical pro-
perties with the surrounding native bone. Regenerative medi-
cine has become an attractive field of study particularly based
on the increasing demand for new solutions to treat significant
tissue loss. This field of study has developed new treatments
which involve the use of cells, growth factors, and biomaterials
either alone or in combination for any tissue type, including
bone.3 Many research projects have focussed on the develop-
ment of advanced biomaterials that accelerate and promote
bone regrowth in defect sites including, more recently, the use
of nanomaterials.4
The field of nanotechnology and the application of nano-
materials to regenerative medicine have significantly advanced
in recent years. There are several reviews studies which have
been published to demonstrate how nanomaterials have been
used in medicine1,5–7 particularly in bone regeneration.8–17
Most of these papers have reviewed specific areas; for instance,
Boccaccini et al. reviewed the application of glass-based nano-
composites in bone regeneration,9 Gu et al. studied the appli-
cation of nanotechnology in the targeted drug delivery for
bone regeneration,11 the progress in nanotechnology for the
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treatment of osteoporosis was evaluated in another review
paper,15 and Wang et al., in their review study, investigated the
interaction of nanomaterials with growth factors and cells for
bone repair.16
Properties of nanostructured biomaterials should be exten-
sively studied for successful bone regeneration. It has been
known that the mechanical properties, biocompatibility, and
osteoinductivity of biomaterials are important criteria to influ-
ence bone regeneration.18,19 The bone formation response can
also be changed by altering the mechanical environment.20 In
addition, the biocompatibility of biomaterials play an impor-
tant role in their performance for bone healing, and their
osteoinductivity would be the most important property of bio-
materials which induces new bone formation.21 Therefore, we
consider how nanotechnology has been applied to modify
tissue engineering scaffolds for bone in three key areas;
mechanical properties, biocompatibility, and osteoinductivity,
in this paper (Fig. 1). Furthermore, the current challenges and
future directions are discussed.
Mechanical properties
Progress
Mechanical forces can play important roles in bone reconstruc-
tion and formation.20,22 Bone cells are responsive to local
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Fig. 1 Different shape & type of nanostructured materials and application of nanotechnology in the improvement of 3 main properties of tissue
engineering scaffolds including mechanical properties, biocompatibility, and osteoinductivity.
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mechanical stresses supplied during motion. These stresses
can contribute to changes in cellular metabolism and influ-
ence bone remodelling by inducing signalling and biochemi-
cal cascades.20 Furthermore, it has been shown that biomater-
ials with an insufficient mechanical strength or with a higher
mechanical strength than native bone can lead to bone repair
failure and bone loss that might be as a result of weak inter-
facial bonding or stress shielding.21 Therefore, the mechanical
properties of biomaterials for bone repair have to be con-
sidered extensively.
There are many papers in the literature that have demon-
strated how the mechanical properties of biomaterials can be
modified by the application of nanotechnology. The results of
recent studies are summarised in Table 1. Bone matrix, a
natural nanocomposite structure, consists of two major phases
at the nanoscale including organic (collagen) and inorganic
(Hydroxyapatite (HAP)). There is a range of mechanical pro-
perties depending on the type of bone with the elastic
modulus varying from 1 to 20 GPa, and the compressive
strength ranging from 1 to 100 MPa dependent on its porosity,
composition and structure.23,24 Various effects of nano-
materials on the mechanical properties of these nano-
composites have been reported and is dependent upon the
nanoparticle dispersion state, surface area, polydispersity, and
organo-modification to improve interface interaction between
phases.25 Studies have shown how incorporation of nanosized
materials, including HAP and bioglass(BG), can improve their
mechanical properties compared to their microsized
equivalents.26–29 We have also showed that the elastic modulus
of porous scaffolds can be enhanced by the addition of nano
BG to the polymeric matrix.30 The chemical and thermal ana-
lysis in our study demonstrated a favourable interaction
between polymer and bioglass nanoparticles which enhanced
the interaction of the two phases at the interface31 and conse-
quently enhanced stiffness. It has also been shown that
the homogenously dispersed nanoparticles are also effective
in increasing the stiffness of synthetic polymer-based
materials.25
Challenge
Despite the fact that there have been many attempts to fabri-
cate scaffolds with appropriate mechanical properties, porous
scaffolds that mechanically behave similarly to bone are yet to
be reported (Fig. 2A). Although some dense nanocomposites
have been developed that exhibit an elastic modulus and
strength in the range of cancellous bone, regrowth of bone
cannot be expected in such non-porous structures and these
do not allow for tissue infiltration. It has been demonstrated
that interconnected porous scaffold networks that enable the
transport of nutrients, removal of wastes, and facilitate pro-
liferation, migration of cells, and vascular ingrowth are essen-
tial for bone tissue engineering.34
Although scaffolds with enhanced mechanical properties,
through the incorporation of nanomaterials, have been
reported by numerous researchers, our fundamental knowl-
edge of the “nano effect” in terms of mechanical properties is
not fully developed (Fig. 2B and C). Challenges in the visualisa-
tion at the nanoscale hinders our understanding of the extent
and properties of the interphase region. The properties of
the interphase layer in nanocomposites has therefore been
mostly investigated by indirect methods such as thermal ana-
lysis.35 Furthermore, a variety of analytical and computational
models have been developed to analyse and predict
the mechanical behaviours of nanomaterials and nano-
composites,36 but the complexity of generating experimental
data, the lack of knowledge about the interphase region, and
the high computational costs have limited the development of
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models that can precisely predict the properties of the various
types of nanocomposites.
The interactions between cells and their pericellular
environment when growing within scaffolds of various
stiffness remains relatively unexplored (Fig. 2C).37 However, it
has been shown that cells can sense the rigidity of the extra-
cellular matrix (ECM) in 2D environments through cell surface
receptors such as integrins.38 Integrins can regulate cell
migration, proliferation, and differentiation by connecting the
intracellular cytoskeleton to the ECM. This activates focal
adhesion kinase (FAK) and phosphoinositide 3-kinase (PI3K)
signaling pathways to regulate the self-renewal and prolifer-
ation of cells, and has been demonstrated with mesenchymal
stem cells.39 It is still not clear how the mechanical properties
of scaffolds stimulate cells to secret the proteinaceous pericel-
lular matrix associated with osteogenesis in a 3D environment.
Therefore, there are no defined values for the desired elastic
modulus and mechanical strength of scaffolds suitable for
bone regeneration. The main challenges in the development of
scaffolds with defined mechanical properties from nano-
structured materials are summarised in Fig. 2B.
Perspective
Innovative fabrication methods, such as 3D printing,40 can be
utilised to not only design and control scaffold porosity but
also to improve mechanical properties through macroscale
scaffold structure design. The application of different shapes
of nanomaterials, including nanorods41,42 and nanowires,43
with homogeneous distribution and high interaction with the
matrix interface can also enhance the strength and elastic
modulus. Although, there are several ways to re-enforce porous
scaffolds improve their mechanical properties, the main ques-
tion, however, is how important is the initial mechanical simi-
larity between a porous scaffold and bone in the defect site for
bone regeneration? (Fig. 2D).
It has been shown that the growth of bone in the implanted
porous scaffolds can improve the mechanical properties of the
regenerated bone in the defect site.44–47 Another study has
suggested that stem cells take part in a bi-directional inter-
action between the features of their 3D surroundings and their
own secreted pericellular matrix and these interplays induce
cellular fate.37 Kolambkar et al. and Reichert et al. demon-
strated that incorporation of growth factors in scaffolds with
low mechanical strength (such as hydrogels) can induce bone
regeneration with the desired resulting stiffness and torsional
strength.45,47 It has also been illustrated that some gels can
mechanically play the same role as autografts after implan-
tation.46 These results reduce the importance of the initial
similarity of the mechanical properties of the scaffold to native
bone. They also suggest the feasibility of developing porous
osteoinductive scaffolds, with lower mechanical properties
than the surrounding bone, which can stimulate and acceler-
ate new bone formation to such an extent that the new bone
can quickly become load bearing.
Biocompatibility
Progress
It has been demonstrated that topographical features at
different length scales, ranging from nano- to micrometre, can
have significant impact on cell adhesion and morphology. In
particular, it has been discussed in the literature that there
could be an optimum size range in which cell adhesion would
be enhanced most significantly but this is dependent on
cell.48 We have reviewed previously how cellular focal adhe-
sions interact with various nanotopographies and discussed
how these interactions can be controlled to direct stem cell
fate.49,50 In fact, cell migration, proliferation, and differen-
tiation are all dependent upon adhesion.48–51 In normal phys-
iological conditions, tissue re-organisation (e.g. during wound
healing) is influenced by the bidirectional flow of information
exchanged between cells and the ECM and this steers impor-
tant cell functions such as adhesion, differentiation, and
migration.51 There is opportunity for this phenomenon to be
recreated on biomaterials. Because focal adhesions are
assembled from the clustering of many integrins (on the nano-
scale),49 the design of nanostructured materials (including
nanomaterials, nanocomposites and nanotopographical fea-
tures) can preferential guide the formation of focal adehsions
and thereby regulate cell fate through changes in both cell bio-
chemistry and cell morphology. Based on this, the application
of nanomaterials as scaffolds should serve as an optimised
reproducible environment for cell attachment, proliferation
and function over other scaffold designs. The results of studies
conducted to investigate the biocompatibility of nanomaterials
and nanocomposites are summarised in Table 2.
An example is given by the study published by Webster and
colleagues which demonstrated that osteoblast adhesion was
significantly (p < 0.01) greater after 4 h when these cells were
cultured on nanophase alumina, titania, and HAP than on
microphase formulations of the same ceramics.52
Furthermore, another study demonstrated that osteoblast
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function and cellular activity were promoted on a nano-
structured metallic surface in relation to a coarse-grained
counterpart.53 Results of Palin and colleague’s research also
showed that nanostructured surfaces (nanophase titania and
PLGA moulds of nanophase titania), without the influence of
any other surface properties, improved adhesion and prolifer-
ation of osteoblasts.54 Xu and co-workers used injectable
nano-apatite scaffolds for cell/growth factor delivery for bone
regeneration. Created pores within the nano-apatite scaffolds
were suitable for cell infiltration. The new scaffolds were bio-
compatible and promoted the adhesion and growth of osteo-
blast-like cells. The cells could infiltrate into the matrix pores,
create cell–cell junctions, and adhere to the nano-apatite
pores’ walls.55 Moreover, it has been shown that nano-bioglass
can induce higher rates of cell proliferation and higher mRNA
expression of osteogenic markers compared to micro-bio-
glass.56 Studies from our laboratories also showed that cells
attach and proliferate highly on polymer/nBG scaffolds (PHB/
nBG), and proved that there may be an optimal nanobioglass
concentration for proliferation and osteoconduction.57
In another study, the effect of the various sizes of hydroxy-
apatite (HAP) nanoparticles (20, 40 and 80 nm), prepared as a
film, on the proliferation of two bone-related cells, bone
marrow derived mesenchymal stem cells (MSCs) and osteosar-
coma cells (U2OS and MG63), were investigated. The results
showed enhanced biocompatibility of films containing nano-
particles as compared with rod-like HAP with a length of hun-
dreds of nanometres. The 20 nm nanoparticle films supported
higher cell viability and proliferation of MSCs. But when the
bone tumour cells were cultured on the HAP nanoparticles,
the opposite phenomenon occurred. In fact, the proliferation
of U2OS and MG63 cells was inhibited by the presence of the
nanoparticles which was inversely proportional to the particle
diameter.58
Furthermore, it has been demonstrated in a separate study
that the orientation of cytoskeletal networks and expression of
focal adhesion proteins and subsequently the adhesion,
spreading and migration of SaOS-2 human osteoblast-like cells
were affected by nano-TiO2 particles in a size dependent
manner.67 They investigated the cells exposed to clinically rele-
vant concentrations (0.05, 0.5, 5 mg L−1) of 5 and 40 nm
spherical nano-TiO2. The actin and microtubule cytoskeletal
networks were disrupted by treatment with nano-TiO2 leading
to morphological modifications of SaOS-2 cells and the cell
Fig. 2 (A) Elastic modulus/compressive strength of the various type of materials compared to human bone. (B) Associated challenges in terms of
assessing the mechanical properties at the nanoscale when developing scaffolds for bone regeneration. (C) Schematic presentation of interactions
between cells and their pericellular environment when growing within scaffolds with unknown parameters. (D) Importance of initial similarity of the
mechanical property of scaffolds to the bone. Although the goal is that the regenerated bone behaves similarly to the natural bone, there are several
studies that have reduced the importance of the initial similarity in the mechanical properties of tissue engineered scaffolds to the bone.
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migration was significantly impaired in cells exposed to 5 nm
nanoparticles compared to unexposed cells. Therefore, the bio-
compatibility and cytotoxicity of materials that incorporate
nano-particles influences the subsequent cellular response
and further studies are required prior to development for clini-
cal application.
Challenge
Despite the progress made so far, there are still some chal-
lenges associated with the biocompatibility or cytotoxicity of
the various nanotechnologies applied to bone regeneration
(Fig. 3A). It is believed that the main mechanism of nanotoxi-
city is the high level of reactive oxygen species (ROS) produced
in the cells,68 which might damage cells and cause sequent
dysfunctions to the cellular microenvironment through down-
stream effects, including peroxidising lipids, disrupting DNA
and altering gene transcription. Unlike regular chemical toxi-
cants, nanomaterials cannot be fully defined for toxicity by
determining their chemical composition and purity. Moreover,
it has not been fully understood how and why nanomaterials
differ from their bulk counterparts in toxicity, which also adds
to the complexity of understanding nanotoxicity.
The cytotoxicity of nanomaterials is synthetically affected by
multiple particular characteristics, including chemical compo-
sition, size, shape, surface charge, solubility, and dose, which
have been well reviewed by some papers.68,69 For instance, the
size of the nanoparticle (NP) is critical for toxicity and it seems
smaller NPs would compromise cell activity more, which is
probably because of the increasing reactivity of NPs with
decreasing size.70 The shape of nanomaterials would also
make a difference and spherical NPs are usually easier and
faster for endocytosis than tube- or fibre-like NPs.71 Despite
the growing work in nanomaterials toxicity determination,
there is still a demand for comprehensive and reliable charac-
terisation of nanomaterials regarding their characteristics indi-
cated above. For example, there are various methods to deter-
mine the size of NPs (e.g. dynamic light scattering, scanning
electron microscopy, transmission electron microscopy, and
atomic force microscopy), but it remains a challenge to unify
the measurement because of the disagreement of values given
by the different methods due to different principles behind
these techniques.72 In addition, the measured size during
preparation might not represent the actual size on site in
application because of possible aggregation/agglomeration
and other reactions caused by dispersion within the physico-
chemical environment. Such reactions also add to the
difficulty of determining the actual effects of shape and
surface charge on toxicity.
With respect to conducting biocompatibility assays, both
in vitro (e.g. live/dead staining, MTT, DLH, and immunochem-
istry) and in vivo (e.g. blood compatibility and pharmacoki-
netics study) methods have been used. The in vitro assay,
which is typically based on 2D cultured cells, is usually the
first to be conducted because of its ease and quick outcome of





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































specific measurements for evaluating the toxicity of a new
nanomaterial, but it cannot elucidate the mechanism
of cell damage and death. In addition, in vitro results
might not represent the in vivo outcomes because of their
different microenvironments (2D versus 3D) and timescales of
toxicity.73
With respect to bioactivity, the inclusion of nanoHAP
(n-HAP) within scaffolds has gained much interest. HAP, as a
ceramic component of natural bone, is osteoconductive (sup-
porting bone formation) and not osteoinductive (stimulation
of osteogenesis).74 HAP is able to support bone formation but
cannot promote it, and the capability to stimulate osteogenesis
is essential for materials to be used in bone regeneration. By
implanting scaffolds fabricated from HAP, it cannot be
expected that the newly formed bone demonstrates the same
natural bone composition and structure, because the HAP is
not highly degradable, and even if the cells migrate and grow
inside the scaffolds, the arrangement of HAP around cells will
be different from what we observe in natural bone. For
example, Dasgupta and colleagues developed scaffolds by
using gelatin-chitosan (GC) and GC composites containing
30 wt% n-HAP (GCH 30) which demonstrated that GCH 30
showed significant improvement in the compressive strength.
MSC proliferation and differentiation on this scaffold observed
in vitro, compared to the other GC scaffold formulations but
when assesed in vivo, lacked bone formation following implan-
tation, and no significant difference to the other GC scaffold
formulations following 1, 2, 3 months after implantation.75 In
another study, Kuttapan and colleagues fabricated a composite
scaffold of silica coated nanohydroxyapatite (nHAP)-gelatin
reinforced with electrospun poly(L-lactic acid) (PLLA) yarns,
and also observed poor bone formation in the nanocomposte
scaffolds when they were not loaded any growth factors follow-
ing 4 and 12 weeks implantation in vivo.76 Nanostructured
materials-tissue interactions in vivo therefore, are not necess-
arily predicted by in vitro assays due to the various com-
ponents involved in regeneration that cannot be replicated
easily in vitro.77
Perspective
There is an increasing tendency to introduce ions in n-HAP
containing materials to improve the biocompatibility of HAP
such as fluoride and magnesium ions. In particular,
Whitlockite (WH) is a kind of calcium phosphate existing in
natural bone tissue and contains Mg.78 Recent results from
the incorporation of WH within scaffolds show higher cell pro-
liferation and differentiation compared to scaffolds containing
HAP alone. The incorporation of WH, HAP, bioglass or
ceramic phase in the fabrication of scaffolds should be con-
sidered with respect to their degradability, bioresorbability,
and their functionality during and after bone regeneration. We
have previously reviewed how calcium and phosphate ion con-
centrations in the cells and in the ECM can promote and
inhibit mineralisation. In addition, there are still several unan-
swered questions related to calcium phosphate particles that
are associated with mineralisation.79 On the other hand, some
studies have shown that scaffolds containing no ceramic
phase, particularly hydrogels with incorporated growth factors,
were also able to induce mineralisation.80,81 For instance, Yan
and colleagues developed a hydrogel system by using hyaluro-
nic acid (HA) and modulating BMP-2 release, and the in vivo
experiments with these hydrogels clearly illustrated early min-
eralisation (in just two weeks).81 We have also demonstrated
the application of an Alginate/ECM hydrogel system with
incorporated stem cells and growth factors for in vivo bone for-
mation in which the bone ECM component showed an
increase in mineralisation compared to irradiated Alginate/
ECM (U.V. irradiation was performed to inactivate endogenous
growth factors within bone ECM).82 These studies suggest that
if the cellular microenvironments is well designed, not only
can the cells fabricate their own ECM-like collagen, but also
the ceramic phase can be naturally formed in an appropriate
arrangement around the cells, and potentially the bone can be
functionally regenerated.
In addition, as mentioned, several unsuccessful animal
studies have been reported despite earlier promising in vitro
Fig. 3 (A) Route of nanotechnology applications in bone regeneration and the associated challenges in terms of biocompatibility. (B) Translatability
of current in vitro studies for clinical applications.
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data. There is therefore a need to develop better standards for
cell characterisation and to design bioreactors which simulate
tissue regeneration in vivo.83 In this regard, micro and nano-
fabrication technologies can be useful. The microenvironment
can be simulated by the design of advanced microfluidic
systems, and scaffolds can be tested and approved in these
developed systems before in vivo implantation (Fig. 3B).
Though many nanomaterials seem to be nontoxic and even
yield beneficial effects for the body, solid risk assessment is
still necessary to address the possible concerns of the public
and end-users. Regarding the internal challenges above, there
is a great demand for establishing standards and guidelines to
determine the biocompatibility of nanomaterials and nano-
technologies in biomedical applications, e.g. bone regener-
ation. The ultimate standards should cover all the aspects
throughout the pathway from the comprehensive characteris-
ation of nanotechnologies/nanomaterials to reliable toxicity
assessment methods. The US National Institute of Standards
and Technology (NIST) released the world’s first reference
material (RM) standards of gold nanoparticles (AuNPs) (10, 30
and 60 nm in diameter) in 2008 and has published some other
RMs since then. Nelson et al.84 tested the genotoxicity of these
NPs based on HepG2 cells and concluded that the NIST AuNPs
could be potentially used as negative-control nanoparticle RMs
for in vitro and in vivo genotoxicity studies. More RMs stan-




Osteoinduction is defined as the ability to stimulate the differ-
entiation of stem cells or osteoprogenitor cells to mature bone-
forming cells,85,86 and it is the process by which osteogenesis
is encouraged. Finally, it is defined as ‘action or process of sti-
mulating osteogenesis’ agreed in the 2018 Chengdu consensus
conference.86 It is necessary to conduct an in vivo test of any
new biomaterial before classifying it as osteoinductive, even if
the material had shown great potential in vitro. García-Gareta
et al.87 have shown that osteoinductivity is an isolated
phenomenon, which is influenced by the chemistry and struc-
ture of the biomaterials. Many studies investigating osteoin-
duction describe bone formation after 8 weeks implantation,
but the time after implantation should be in direct correlation
with the size of the animal model used due to the fact that
bone formation in larger animals is a slower process. There
are some studies that have investigated the application of
Fig. 4 Associated challenges in terms of osteoinductivity for nanostructured materials in bone regeneration.
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nanotechnology to enhance the osteoinductive properties of
new biomaterials in vivo; the results of these studies are sum-
marised in Table 3.
Wu et al. showed n-TiO2/polyether ether ketone (PEEK)
could enhance bone regeneration around the implant in a
canine model (implants were placed in each animal on the
medial surface of each tibia in the proximal diaphyseal
region).88 In another study, it has been shown that nHAP (as a
composite of nanohydroxyapatite and pullulan/dextran poly-
saccharides) activates early calcification and osteoid tissue for-
mation in non-osseous and osseous sites in different animal
models such as the femoral condyle of rat, a transversal man-
dibular defect and a tibial osteotomy in goat.89
Novel nanohydroxyapatite sonocoated scaffolds were
studied for bone regeneration by Rogowska-Tylman.90 A
uniform layer of nanohydroxyapatite particles with a thickness
within the range of 200 to 300 nm was sonocoated on two
types of scaffolds: a porous β-TCP ceramic scaffold and a 3D-
printed scaffold made of PCL fibers. In vivo tests in rabbits
confirmed that the novel coating stimulated new tibial bone
tissue formation, occupying 33% of the initial scaffold volume
for the nHAP-coated PCL scaffold and 68% for the nHAP-
coated β-TCP after 3 months.
M. Gong and colleagues92 have developed a core-sheath
micro/nano fibre membrane consisting of a polycaprolactone
core and gelatine shell loaded with the antibacterial drug mox-
ifloxacin hydrochloride (MOX) and a traditional Chinese medi-
cine called icariin (ICA) as biomimetic artificial periosteum to
promote bone regeneration. They tested this material in vivo,
in a rabbit radius defect model to test the formation of bone.
They demonstrated that the dual drug-loaded nanofibers
enhanced the quality and quantity of bone formation as well
as maturation when compared to control groups.
An injectable DNA-loaded nano-calcium phosphate paste
was prepared to be used as a bioactive bone substitution
material by Schlickewei and colleagues.93 Calcium phosphate
nanoparticles were loaded with BMP-7- and VEGF-A-encoding
DNA prior to implantation in a rabbit critical-size tibial bone
defect and observed over 2, 4 and 12 weeks following surgery.
The calcium phosphate paste without DNA led to regular
healing of the critical-size bone defect, but the healing was
slower than the DNA-loaded paste. Thus, the in situ transfec-
tion with BMP-7 and VEGF-A significantly improved the poten-
tial of calcium phosphate as a pasty bone substitution
material. Over the last decade, several nanotechnologies94,95
have been applied to biomaterials fabrication and these
approved for use in clinical applications. For example, Vitoss
(Orthovita), approved by the FDA in 2000, is a three-dimen-
sional scaffold composed of ultraporous beta-tricalcium phos-
phate (TCP) NPs (mean size 100 nm). These nanoparticles are
used in repairing bone defects by enhancing resorption and
stimulating new bone growth. However, in a FDA document
published in 2003 related to this product,96 Vitoss scaffolds
were advised to not be used to treat large defects. In 2008,97
they reported the scaffolds functioned as intended in all cases,






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the scaffolds has not yet been correlated to human clinical
experience. In addition, a clinical trial also demonstrated that
the nanostructured biphasic calcium phosphate is biocompati-
ble and osteoconductive, and that the implants remained
in situ after 3 and 6 months without complications or loss of
the implants and with preservation of the alveolar architec-
ture.98 The number available studies regarding in vivo new
bone formation in human is limited, which gives researchers a
limited understanding of the detailed mechanism of bone
development in these materials. This section of the review
illustrates the lack of studies in this area as well as the need
for further in vivo and clinical studies on this matter.
Challenge
Nonetheless, the application of nanotechnology to biomater-
ials development for bone has developed rapidly in recent
years, and it has been shown that such materials can stimulate
bone formation in vivo. However, there are still several chal-
lenges in the regeneration of critical sized bone defects
(Fig. 4).99 The insufficient number of stem cells in the defect
site for differentiation to osteocytes, lack of cell penetration
and migration to the defect zone, lower levels of vascularisa-
tion to supply nutrients and exchange waste materials for the
cells could be the factors that impact on inadequate bone
regeneration in the critical bone defects.
Angiogenesis and osteogenesis are closely linked and they
must be significantly considered for physiological bone func-
tion. It is demonstrated that changes in vascular growth can
compromise physiological bone formation, for instance,
leading to non-union fractures, and osteonecrosis.100,101 On
the other hand, vascular endothelial growth factor (VEGF) is
the main regulator of angiogenesis and has also been reported
to inhibit osteoblast differentiation,102 and VEGF over-
expression can also cause bone resorption.103 This compe-
tition between osteogenesis and angiogenesis inhibits for-
mation of mature blood vessels and interrupts the coupling of
angiogenesis and osteogenesis in bone regeneration.
Furthermore, non-vascularisation in implanted scaffolds inhi-
bits appropriate bone regeneration in defect sites.75 Therefore,
the coupling of angiogenesis and osteogenesis is still one of
the main challenges in bone regeneration, and both should be
investigated when a nanomaterial is suggested for bone tissue
engineering.
Animal models are used to study the osteoinductivity of
nanostructured materials, however, the in vivo interaction of
nanomaterials and biological systems are much more
complex. In addition, bone regeneration in the commonly
used animals for this work (rat, rabbit, sheep) is different com-
pared to man due to species differences in bone regeneration
and healing. Despite large investments in tissue engineering,
the general success rate of biomaterials in clinical develop-
ment remains low.99 The flawed preclinical research is one of
the distinguished explanations, in which the use and outcome
of animal models are critical for clinical translations. Hence, a
validated and predictive animal model must be selected to
address the clinical question. Small animal models are less
expensive and are more straightforward to conduct. However,
they do not always represent mechanistic responses compared
to humans. For instance, mouse and rats show limited intra-
cortical remodelling and their growth plates remain open.
Therefore, the skeletal morphometric and mechanical data
can be impacted by these differences.104
Most nanomaterials, such as gold nanoparticles, are cur-
rently being assessed in in vitro testing platforms without
minimal development towards actual clinical applications.105
There are a few very important factors relevant to the use of
nanoparticles (NPs) for in vivo applications, including their
size and the stimulation of inflammatory response, together
with their osteoinductive properties. If the NPs size is smaller
than 10 nm they may be excreted through the kidneys, whereas
NPs with sizes between 100 to 200 nm will be cleared by the
liver and spleen. Moreover, NPs with sizes from 20 to 100 nm
have been shown to diffuse through the endothelium of
tumour tissues.95 Therefore, particle size plays an important
role in materials development for the intended clinical appli-
cation. Nano-TiO2 particles can enter the blood circulation
and be deposited in the liver, changing biochemical indi-
cators, leading to liver inflammation.106 It has been shown
that long-term inflammation of the liver leads to cell acti-
vation, and multiple signalling pathways can promote the
ECM deposition, causing liver fibrosis. Recently, the progress
on murine liver injury induced by TiO2 has been investigated.
The size of nano-TiO2, its dosage, exposure time, and surface
properties can affect its toxicity. Therefore, the toxic effects of
nano-TiO2 in humans should be investigated in greater depth,
and in more in detail for nano-TiO2 based implants.
Regarding inflammation, some materials are tolerated by
the body, such as polycaprolactone (PCL) or inert bioceramics
that do not elicit a response from the host immune system.3 In
the case of the polyesters, such as PCL, degradation results in
acidic compounds that can affect the intracellular pH and alter
cellular fate. The degradation of polymeric nanoparticles can
induce an inflammatory reaction due to their reduced size and
can be rapidly expelled by the body reducing their therapeutic
efficacy.107 However, previous studies have demonstrated
encouraging data in controlling inflammation in both in vitro
and in vivo experiments. More extensive investigations should
be carried out because the degraded products of the implants
can exist for a long period of time in the body and more exten-
sive screening of type, density, and duration of these signals
should be conducted to evaluate their effects on macro-
phages.108 Finally, the bone engineering community must
study the long-term toxicity of nanomaterials to add confi-
dence to their inclusion in the biomedical field.
Perspective
Nanotechnology alone cannot provide a promising approach
for bone regeneration. The importance of the application of
growth factors such as BMP2, VEGF to enhance osteoinduction
and vascularisation is more of concern in the case of critical-
sized bone defects.76,109,110 VEGF levels must be controlled,
because non-physiological doses can inhibit bone formation,
Review Nanoscale































































































directly influencing osteoblast differentiation and enhancing
bone resorption.111 Current studies of growth factors’ func-
tions should be aimed at further clarifying the molecular
crosstalk between osteogenesis and angiogenesis, and the
association of their dose in bone formation.112 The controlled
release of growth factors and their concentrations are impor-
tant parameters which should be optimised in bone
regeneration.109,113,114 We have developed a new nanotechno-
logy method by coating a nanolayer of poly (ethyl acrylate) on
material surfaces, including biomaterials, that can increase
the bioavailability of fibronectin domains for attachment of
cells and growth factors and consequently, improve bone
regeneration.115–117 In addition, the application of further
nanosystem delivery methods for growth factors and other
osteoinductive factors such as adenosine118 and ions119 can be
explored to support complete bone regeneration. Therefore, it
seems that if advanced fabrication methodologies (such as
computer-aided design (CAD) and rapid prototyping) and
growth factor and metabolite release systems are combined
with nanotechnology, we can hopefully tackle the challenges
of bone formation in critical-sized bone defects and provide
efficacious treatment strategies.
Conclusions
The field of nanotechnology and the application of nano-
materials to regenerative medicine has been a rapidly growing
area of research in recent years. In this review paper, the
impact of nanotechnology in biomaterials development for
bone regeneration has been discussed. The review illustrates
that mechanical properties, biocompatibility, and the osteoin-
ductivity of biomaterials can be improved by the application of
nanomaterials. However, there are still several challenges that
need to be overcome. As this field moves forward, the combi-
nation of nanotechnology with factor delivery including
growth factors, metabolites and ions will inform biomaterials
design with the goal of achieving complete bone regeneration.
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